Satavaptan

Drug Profile

Satavaptan

Alternative Names: Aquilda; SR 121463B; SR-121463

Latest Information Update: 02 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Class Antihypertensives; Heart failure therapies; Morpholines; Small molecules; Spiro compounds
  • Mechanism of Action Vasopressin V2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Glaucoma; Heart failure; Hypertension; Hyponatraemia; Liver cirrhosis; Nephrotic syndrome

Most Recent Events

  • 26 Apr 2009 Adverse events data from a trial in liver cirrhosis presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL-2009)
  • 31 Dec 2008 Discontinued - Phase-III for Cirrhosis in Argentina (PO)
  • 31 Dec 2008 Discontinued - Phase-III for Cirrhosis in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top